News

The CHMP recommendation of OZURDEX (dexamethasone 700mcg intravitreal implant in applicator) is for DME patients who are pseudophakic (have an artificial lens implant), or who are considered insufficiently

The Phase II trial is designed to assess the safety, tolerability and efficacy of RTA 408 Lotion versus vehicle for the prevention and treatment of radiation dermatitis in

According to the companies, the Phase III trial called RESILIENCE failed to meet its primary endpoint of improving progression-free survival (PFS). In the randomized, double-blind, placebo-controlled trial, the

According to Aparna Krishnan, MS, GlobalData’s Analyst, and Joshua Owide, GlobalData’s Director of Healthcare Industry Dynamics, the rationale for the deal consisted of a mix of portfolio diversification,

The company announces that it has achieved effective knock-down of the expression of a target gene in the brain in a sequence-specific manner. Independent analysis of brain tissue

DIL is a world leader in developing and providing the finest products in food technology today. Under the terms of the agreement, DIL will manufacture and supply Fortetropin

TransCelerate BioPharma Inc. is dedicated to making the research and development process more efficient across the pharmaceutical industry. The Shared Investigator Platform, which will be built as an

CanTx and Novogen expect to file an Investigational New Drug (IND) application for Cantrixil early next year and to advance this compound into the clinic by mid- 2015.

The CHMP opinion supports the use of Zydelig in combination with rituximab for the treatment of adult patients with CLL who have received at least one prior therapy